Skip to main content
Erschienen in: Calcified Tissue International 3/2011

01.03.2011 | Original Research

Increased Fracture Risk in Normocalcemic Postmenopausal Women with High Parathyroid Hormone Levels: A 16-Year Follow-Up Study

verfasst von: Lars Rejnmark, Peter Vestergaard, Christine Brot, Leif Mosekilde

Erschienen in: Calcified Tissue International | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

High PTH levels increase bone turnover and decrease bone mineral density (BMD). Low plasma 25-hydroxyvitamin D (25OHD) levels cause secondary hyperparathyroidism, but the relative contribution of low 25OHD and high PTH levels on risk of fracture is largely unknown. Within the cohort of women (n = 2,016) included in the Danish Osteoporosis Prevention Study (DOPS), we studied risk of fracture according to parathyroid status. Analyses were performed on effects of high PTH levels (i.e., in the upper tertile, ≥4.5 pmol/L) on risk of incident fractures at different 25OHD levels during 16 years of follow-up. Incident fractures were assessed using a nationwide hospital discharge register. In addition, effects of high PTH levels on BMD and vertebral fractures were assessed by DXA scans and spinal X-ray examination after 10 years of follow-up. High PTH levels were associated with a decreased body mass index, adjusted BMD, and an increased risk of any fracture (HR = 1.41, 95% CI 1.11–1.79) as well as an increased risk of osteoporotic fractures (HR = 1.59, 95% CI 1.20–2.10). Plasma 25OHD levels per se did not affect fracture risk, but high PTH levels were associated with an increased fracture risk only at 25OHD levels <50 nmol/L and 50–80 nmol/L. High PTH levels did not increase risk of fracture at 25OHD levels >80 nmol/L. In conclusion, PTH levels in the upper part or above the upper level of the reference interval increase risk of fracture in the presence of low vitamin D levels.
Literatur
1.
Zurück zum Zitat Eastell R, Arnold A, Brandi ML, Brown EM, D’Amour P, Hanley DA, Rao DS, Rubin MR, Goltzman D, Silverberg SJ, Marx SJ, Peacock M, Mosekilde L, Bouillon R, Lewiecki EM (2009) Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 94:340–350PubMedCrossRef Eastell R, Arnold A, Brandi ML, Brown EM, D’Amour P, Hanley DA, Rao DS, Rubin MR, Goltzman D, Silverberg SJ, Marx SJ, Peacock M, Mosekilde L, Bouillon R, Lewiecki EM (2009) Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 94:340–350PubMedCrossRef
2.
Zurück zum Zitat Saleh F, Jorde R, Sundsfjord J, Haug E, Figenschau Y (2006) Causes of secondary hyperparathyroidism in a healthy population: the Tromsø study. J Bone Miner Metab 24:58–64PubMedCrossRef Saleh F, Jorde R, Sundsfjord J, Haug E, Figenschau Y (2006) Causes of secondary hyperparathyroidism in a healthy population: the Tromsø study. J Bone Miner Metab 24:58–64PubMedCrossRef
3.
Zurück zum Zitat Lips P (2001) Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 22:477–501PubMedCrossRef Lips P (2001) Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 22:477–501PubMedCrossRef
4.
Zurück zum Zitat Mosekilde L (2005) Vitamin D and the elderly. Clin Endocrinol (Oxf) 62:265–281CrossRef Mosekilde L (2005) Vitamin D and the elderly. Clin Endocrinol (Oxf) 62:265–281CrossRef
5.
Zurück zum Zitat Lips P, Duong T, Oleksik A, Black D, Cummings S, Cox D, Nickelsen T (2001) A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J Clin Endocrinol Metab 86:1212–1221PubMedCrossRef Lips P, Duong T, Oleksik A, Black D, Cummings S, Cox D, Nickelsen T (2001) A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J Clin Endocrinol Metab 86:1212–1221PubMedCrossRef
6.
Zurück zum Zitat Malabanan A, Veronikis IE, Holick MF (1998) Redefining vitamin D insufficiency. Lancet 351:805–806PubMedCrossRef Malabanan A, Veronikis IE, Holick MF (1998) Redefining vitamin D insufficiency. Lancet 351:805–806PubMedCrossRef
7.
Zurück zum Zitat Chapuy MC, Preziosi P, Maamer M, Arnaud S, Galan P, Hercberg S, Meunier PJ (1997) Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 7:439–443PubMedCrossRef Chapuy MC, Preziosi P, Maamer M, Arnaud S, Galan P, Hercberg S, Meunier PJ (1997) Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 7:439–443PubMedCrossRef
8.
Zurück zum Zitat Dawson-Hughes B, Harris SS, Dallal GE (1997) Plasma calcidiol, season, and serum parathyroid hormone concentrations in healthy elderly men and women. Am J Clin Nutr 65:67–71PubMed Dawson-Hughes B, Harris SS, Dallal GE (1997) Plasma calcidiol, season, and serum parathyroid hormone concentrations in healthy elderly men and women. Am J Clin Nutr 65:67–71PubMed
9.
Zurück zum Zitat Brot C, Vestergaard P, Kolthoff N, Gram J, Hermann AP, Sorensen OH (2001) Vitamin D status and its adequacy in healthy Danish perimenopausal women: relationships to dietary intake, sun exposure and serum parathyroid hormone. Br J Nutr 86(Suppl 1):S97–S103PubMedCrossRef Brot C, Vestergaard P, Kolthoff N, Gram J, Hermann AP, Sorensen OH (2001) Vitamin D status and its adequacy in healthy Danish perimenopausal women: relationships to dietary intake, sun exposure and serum parathyroid hormone. Br J Nutr 86(Suppl 1):S97–S103PubMedCrossRef
10.
Zurück zum Zitat Rejnmark L, Vestergaard P, Brot C, Mosekilde L (2008) Parathyroid response to vitamin D insufficiency: relations to bone, body composition, and to life style characteristics. Clin Endocrinol (Oxf) 69:29–35CrossRef Rejnmark L, Vestergaard P, Brot C, Mosekilde L (2008) Parathyroid response to vitamin D insufficiency: relations to bone, body composition, and to life style characteristics. Clin Endocrinol (Oxf) 69:29–35CrossRef
11.
Zurück zum Zitat Sahota O, Gaynor K, Harwood RH, Hosking DJ (2001) Hypovitaminosis D and “functional hypoparathyroidism”—the NoNoF (Nottingham Neck of Femur) study. Age Ageing 30:467–472PubMedCrossRef Sahota O, Gaynor K, Harwood RH, Hosking DJ (2001) Hypovitaminosis D and “functional hypoparathyroidism”—the NoNoF (Nottingham Neck of Femur) study. Age Ageing 30:467–472PubMedCrossRef
12.
Zurück zum Zitat Mosekilde L (2008) Primary hyperparathyroidism and the skeleton. Clin Endocrinol (Oxf) 69:1–19CrossRef Mosekilde L (2008) Primary hyperparathyroidism and the skeleton. Clin Endocrinol (Oxf) 69:1–19CrossRef
13.
Zurück zum Zitat Vestergaard P, Mollerup CL, Frokjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L (2000) Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ 321:598–602PubMedCrossRef Vestergaard P, Mollerup CL, Frokjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L (2000) Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ 321:598–602PubMedCrossRef
14.
Zurück zum Zitat Looker AC, Mussolino ME (2008) Serum 25-hydroxyvitamin D and hip fracture risk in older U.S. white adults. J Bone Miner Res 23:143–150PubMedCrossRef Looker AC, Mussolino ME (2008) Serum 25-hydroxyvitamin D and hip fracture risk in older U.S. white adults. J Bone Miner Res 23:143–150PubMedCrossRef
15.
Zurück zum Zitat Cummings SR, Browner WS, Bauer D, Stone K, Ensrud K, Jamal S, Ettinger B (1998) Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group [see comments]. N Engl J Med 339:733–738PubMedCrossRef Cummings SR, Browner WS, Bauer D, Stone K, Ensrud K, Jamal S, Ettinger B (1998) Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group [see comments]. N Engl J Med 339:733–738PubMedCrossRef
16.
Zurück zum Zitat Tromp AM, Ooms ME, Popp-Snijders C, Roos JC, Lips P (2000) Predictors of fractures in elderly women. Osteoporos Int 11:134–140PubMedCrossRef Tromp AM, Ooms ME, Popp-Snijders C, Roos JC, Lips P (2000) Predictors of fractures in elderly women. Osteoporos Int 11:134–140PubMedCrossRef
17.
Zurück zum Zitat Mosekilde L, Hermann AP, Beck NH, Charles P, Nielsen SP, Sorensen OH (1999) The Danish Osteoporosis Prevention Study (DOPS): project design and inclusion of 2000 normal perimenopausal women. Maturitas 31:207–219PubMedCrossRef Mosekilde L, Hermann AP, Beck NH, Charles P, Nielsen SP, Sorensen OH (1999) The Danish Osteoporosis Prevention Study (DOPS): project design and inclusion of 2000 normal perimenopausal women. Maturitas 31:207–219PubMedCrossRef
18.
Zurück zum Zitat Souberbielle JC, Lawson-Body E, Hammadi B, Sarfati E, Kahan A, Cormier C (2003) The use in clinical practice of parathyroid hormone normative values established in vitamin D-sufficient subjects. J Clin Endocrinol Metab 88:3501–3504PubMedCrossRef Souberbielle JC, Lawson-Body E, Hammadi B, Sarfati E, Kahan A, Cormier C (2003) The use in clinical practice of parathyroid hormone normative values established in vitamin D-sufficient subjects. J Clin Endocrinol Metab 88:3501–3504PubMedCrossRef
19.
Zurück zum Zitat Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333PubMedCrossRef Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333PubMedCrossRef
20.
Zurück zum Zitat Beral V (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419–427PubMedCrossRef Beral V (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419–427PubMedCrossRef
21.
Zurück zum Zitat Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH (1999) The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 46:263–268PubMed Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH (1999) The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 46:263–268PubMed
22.
Zurück zum Zitat Gault MH, Longerich LL, Harnett JD, Wesolowski C (1992) Predicting glomerular function from adjusted serum creatinine. Nephron 62:249–256PubMedCrossRef Gault MH, Longerich LL, Harnett JD, Wesolowski C (1992) Predicting glomerular function from adjusted serum creatinine. Nephron 62:249–256PubMedCrossRef
23.
Zurück zum Zitat Saquib N, von Mählen D, Garland C, Barrett-Connor E (2006) Serum 25-hydroxyvitamin D, parathyroid hormone, and bone mineral density in men: the Rancho Bernardo study. Osteoporos Int 17:1734–1741PubMedCrossRef Saquib N, von Mählen D, Garland C, Barrett-Connor E (2006) Serum 25-hydroxyvitamin D, parathyroid hormone, and bone mineral density in men: the Rancho Bernardo study. Osteoporos Int 17:1734–1741PubMedCrossRef
24.
Zurück zum Zitat Bischoff-Ferrari HA, Dietrich T, Orav EJ, Dawson-Hughes B (2004) Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med 116:634–639PubMedCrossRef Bischoff-Ferrari HA, Dietrich T, Orav EJ, Dawson-Hughes B (2004) Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med 116:634–639PubMedCrossRef
25.
Zurück zum Zitat Heaney RP, Dowell MS, Hale CA, Bendich A (2003) Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 22:142–146PubMed Heaney RP, Dowell MS, Hale CA, Bendich A (2003) Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 22:142–146PubMed
Metadaten
Titel
Increased Fracture Risk in Normocalcemic Postmenopausal Women with High Parathyroid Hormone Levels: A 16-Year Follow-Up Study
verfasst von
Lars Rejnmark
Peter Vestergaard
Christine Brot
Leif Mosekilde
Publikationsdatum
01.03.2011
Verlag
Springer-Verlag
Erschienen in
Calcified Tissue International / Ausgabe 3/2011
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-010-9454-0

Weitere Artikel der Ausgabe 3/2011

Calcified Tissue International 3/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.